CSIMarket
 


Madrigal Pharmaceuticals Inc   (MDGL)
Other Ticker:  
 

Madrigal Pharmaceuticals Inc 's Working Capital Ratio

MDGL's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth




MDGL Working Capital Ratio (Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Current Liabilities Change 42.43 % 47.64 % 57.25 % 65.29 % 40.51 %
Y / Y Current Assets Change -48.14 % -34.2 % -28.2 % -4.73 % -10.26 %
Working Capital Ratio MRQ 1.6 2.58 2.9 3.55 4.4
Overall Ranking # # # # #
Seq. Current Liabilities Change 18.08 % 9.06 % -0.27 % 10.9 % 22.4 %
Seq. Current Assets Change -26.77 % -2.99 % -18.59 % -10.32 % -7.09 %



Working Capital Ratio third quarter 2022 Comment
Due to increase in Current Liabilities in the third quarter 2022, Working Capital Ratio fell to 1.6 above Madrigal Pharmaceuticals Inc average.

Within Major Pharmaceutical Preparations industry Madrigal Pharmaceuticals Inc booked the highest Working Capital Ratio than Madrigal Pharmaceuticals Inc in the third quarter 2022. While total ranking remained unchanged compare to previous quarter at no. .

Explain Working Capital Ratio
Where is MDGL most successful ?
Working Capital Ratio MDGL on the trailing twelve month basis
Working Capital Ratio third quarter 2022 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall Market #


Working Capital Ratio Statistics
High Average Low
0 0 0
 




Financial Statements
Madrigal Pharmaceuticals Inc 's Current Liabilities $ 98 Millions Visit MDGL's Balance sheet
Madrigal Pharmaceuticals Inc 's Current Assets $ 157 Millions Visit MDGL's Balance sheet
Source of MDGL's Sales Visit MDGL's Sales by Geography


Cumulative Madrigal Pharmaceuticals Inc 's Working Capital Ratio

MDGL's Working Capital Ratio for the trailling 12 Months

MDGL Working Capital Ratio

(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Current Liabilities TTM Growth 42.43 % 47.64 % 57.25 % 65.29 % 40.51 %
Y / Y Current Assets TTM Growth -48.14 % -34.2 % -28.2 % -4.73 % -10.26 %
Working Capital Ratio TTM 2.59 3.32 4.04 4.83 5.56
Total Ranking TTM # 412 # 1460 # 804 # 726 # 1188
Seq. Current Liabilities TTM Growth 18.08 % 9.06 % -0.27 % 10.9 % 22.4 %
Seq. Current Assets TTM Growth -26.77 % -2.99 % -18.59 % -10.32 % -7.09 %


TTM Working Capital Ratio Comment
On the trailing twelve months basis Due to increase in Current Liabilities in the III. Quarter to $98.16 millions, average cumulative Working Capital Ratio decreased to 2.59 below the Madrigal Pharmaceuticals Inc average Working Capital Ratio.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operatig within Major Pharmaceutical Preparations industry 50 other companies have achieved higher Working Capital Ratio than Madrigal Pharmaceuticals Inc . While overall ranking remained unchanged compare to previous quarter at no. 412.

Explain Working Capital Ratio
Where is MDGL most successful ?
Working Capital Ratio MDGL on the trailing twelve month basis

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 51
Healthcare Sector # 178
Within the Market # 412


TTM Working Capital Ratio Statistics
High Average Low
62.76 20.93 2.57
(Mar 31 2019)   (Sep 30 2022)




Companies with similar Working Capital Ratio in the quarter ending Sep 30 2022, within Major Pharmaceutical Preparations Industry Working Capital RatioSep 30 2022 MRQ Current AssetsSep 30 2022 MRQ Current Liabilities
Vaccinex Inc   4.40 $ 8.025  Millions$ 1.824  Millions
2seventy Bio Inc   4.37 $ 349.417  Millions$ 79.897  Millions
Kiniksa Pharmaceuticals Ltd   4.28 $ 241.815  Millions$ 56.492  Millions
G1 Therapeutics Inc   4.24 $ 157.465  Millions$ 37.134  Millions
Prophase Labs Inc   4.21 $ 70.326  Millions$ 16.693  Millions
Mirum Pharmaceuticals Inc   4.19 $ 215.556  Millions$ 51.398  Millions
Axsome Therapeutics Inc   4.19 $ 252.383  Millions$ 60.283  Millions
Emergent Biosolutions Inc   4.17 $ 1,118.500  Millions$ 268.400  Millions
Y mabs Therapeutics inc   4.16 $ 133.244  Millions$ 32.015  Millions
Gt Biopharma Inc   4.15 $ 20.872  Millions$ 5.025  Millions
Travere Therapeutics Inc   4.08 $ 534.842  Millions$ 131.032  Millions
Beigene Ltd   4.07 $ 5,749.168  Millions$ 1,411.311  Millions
Pacira Biosciences inc   4.06 $ 533.411  Millions$ 131.526  Millions
Theriva Biologics inc   4.00 $ 52.731  Millions$ 13.192  Millions
Horizon Therapeutics Public Limited Company  3.96 $ 3,412.009  Millions$ 860.614  Millions
Galera Therapeutics Inc   3.86 $ 44.917  Millions$ 11.632  Millions
Corbus Pharmaceuticals Holdings Inc   3.86 $ 67.348  Millions$ 17.469  Millions
Vtv Therapeutics Inc   3.85 $ 28.783  Millions$ 7.467  Millions
Dynavax Technologies Corporation  3.82 $ 932.944  Millions$ 244.080  Millions
Ani Pharmaceuticals inc  3.79 $ 309.377  Millions$ 81.627  Millions
Endo International Plc  3.78 $ 2,054.162  Millions$ 543.053  Millions
Societal Cdmo Inc   3.78 $ 49.494  Millions$ 13.105  Millions
Karyopharm Therapeutics Inc   3.77 $ 222.677  Millions$ 58.991  Millions
Amphastar Pharmaceuticals Inc   3.76 $ 384.222  Millions$ 102.190  Millions
Calithera Biosciences Inc   3.76 $ 34.697  Millions$ 9.232  Millions
Alpine Immune Sciences Inc   3.70 $ 253.239  Millions$ 68.459  Millions
Corvus Pharmaceuticals Inc   3.67 $ 51.272  Millions$ 13.978  Millions
Mannkind Corporation  3.66 $ 218.381  Millions$ 59.597  Millions
Theravance Biopharma inc   3.60 $ 511.718  Millions$ 142.132  Millions
F star Therapeutics Inc   3.58 $ 49.609  Millions$ 13.849  Millions

Date modified: 2022-11-09T12:42:54+00:00

Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

TKNO's Profile

Stock Price

TKNO's Financials

Business Description

Fundamentals

Charts & Quotes

TKNO's News

Suppliers

TKNO's Competitors

Customers & Markets

Economic Indicators

TKNO's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071